Keyword Tag Sort by

Carcinoid News (1 article)

Phase III Novartis data show potential benefit of Afinitor® plus Sandostatin® LAR® in patients with advanced neuroendocrine tumors

Everolimus plus octreotide LAR extended time without tumor growth from 11.3 to 16.4 months versus octreotide LAR alone in advanced NET (carcinoid) patients[1] The study did not reach its primary endpoint of progression-free survival[1] Analyses to adjust for imbalances in...

Published on 11 October 2010, 08:28
image

Interested in Carcinoid News?

Subscribe to daily Science News
(a free e-mail delivery powered by Google)

Top Categories

Alzheimer Astronomy Bacteria Biochemistry Biology Blood Brain Breast Cancer Cancer Cell Biology Chemistry Climate DNA Depression Diabetes Diseases Drugs Ecology Energy Engineering Environment Enzymes Genes Genetics Global warming HIV Health Hormones Immune system Life Sciences Marine Science Materials Science Medicine Molecular Biology Nanotechnology Neuroscience Obesity Physics Plants Pregnancy Proteins Psychology Space Stem cells Technology Vaccines Viruses Vision chemotherapy prostate cancer

image

We have launched our peer- reviewed, Open-access journal: Insciences Journal

Recently added

27.11.12
Consequential Life Cycle Assessment of Nitrogen Fertilisers Based on Biomass – a Swedish perspective

08.11.12
From Molecular Hollows to Imprinting Strategies – Mass-Sensitive Devices in Host-Guest Chemistry

26.04.12
CdSe/ZnSe Quantum-Dot Semiconductor Optical Amplifiers

23.03.12
Screen-printed Electrochemical Sensors and Biosensors for Monitoring Metal Pollutants